Packing batteries with more punch
Indian researchers are working on cells that can store more energy, last longer
The U.S. Food and Drug Administration (FDA) has raised doubts about Strides Pharma Sciences Ltd's quality-control practices after finding adulteration and evidence of “uncontrolled shredding of documents” at one of its plants.
The FDA found “significant violations” of current good manufacturing practice (CGMP) regulations at Strides Pharma's plant in Puducherry , the drug regulator said in a warning letter that was made public on Tuesday.
Shares of the Bangalore-based company, which fell as much as 8% to a near one-year low earlier on Wednesday, were trading down 2.9% at 1.45 pm.
Last month, Aurobindo Pharma Ltd was warned by the FDA for ignoring impurities in an active ingredient it produced. Hyderabad-based Aurobindo recalled contaminated valsartan in January and in March.
Also read: USFDA issues warning letter to Aurobindo Pharma
The destruction of quality-control paperwork by Strides and a lack of adequate documentation that its medicines are safe ”raise questions about the effectiveness” of Strides's quality unit “and the integrity and accuracy” of its data, said Francis Godwin, director of the FDA's Office of Manufacturing Quality, in the letter.
The regulator said an investigator found a binder containing CGMP records, including batch records for U.S. drug products, discarded with other records in a 55-gallon drum in Stride's scrap yard.
“CGMP documents in the binder were dated as recently as January 21, 2019: seven days before our inspection. Your quality unit did not review or check these documents prior to disposal,” Godwin said in the letter, addressed to Strides Chief Executive Officer Arun Kumar.
On July 2, Strides shares slumped after it said it received a warning letter from the U.S. FDA, it did not disclose the content of the letter at that time.
A Strides spokesman said on Wednesday the company won't be making any further comments.
Strides bought a unit of Vivimed Labs Ltd in January. Vivimed manufactures losartan, a drug that is part of a wider recall in the United States.
The FDA's warning letter dated July 1 comes months after several Indian drugmakers including Sun Pharmaceutical Ltd and Dr.Reddy's Laboratories Ltd were named in a U.S. lawsuit against Israeli drugmaker Teva Pharmaceutical Industries Ltd accusing it of conspiring to inflate drug prices and stifle competition for generic drugs.
Indian researchers are working on cells that can store more energy, last longer
To fix a broken bone, doctors often harvest another bone from the patient’s body or from someone else. It ...
Superconductors from IIScScientists at IISc Bangalore have invented a device with a nanocrystal structure ...
Engineering and construction giant L&T has won a licence from the Council of Scientific & Industrial ...
Will a stock continue its current trend or will it reverse? We tell you how you can read chart patterns to ...
Sensex and Nifty 50 saw selling interest on Friday and slumped; selling pressure could continue
Investors with a long-term horizon can consider this offer
Most AMCs have been sending out cryptic e-mails. We tell you how to read between the lines
In these isolated times when people yearn for a slice of the familiar, amateur and professional chefs are ...
Forget the tuna. The island nation will keep you full and happy with coconut, koftas and jasmine
This year, on Facebook, I saw that someone had posted a list of EASY RESOLUTIONS. I didn’t copy them down but ...
With strokes of quirky humour, Partha Pratim Deb uses pulp, terracotta, glass and discarded cloth to create ...
Digital is becoming dominant media, but are companies and their ad agencies transforming fast enough to make a ...
Slow Network, promoted by journalist-lyricist Neelesh Misra, pushes rural products and experiences
How marketers can use the traditional exchange of festive wishes meaningfully
For Fortune, a brand celebrating its 20th anniversary, it was a rude shock to become the butt of social media ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor